Redeye provides an initial take following SciBase’s Q2 2026 report. We are positive about the sales development, which was broadly in line with our expectations. However, costs came in higher than expected. Overall, our initial view of the report is mixed, although the long-term outlook remains strong. In our upcoming research update, we expect to make some fine-tuning to our sales estimates while taking into account the higher-than-expected costs during the quarter. Our Base Case is expected to slightly decrease, although we do not expect any major changes and still see clear upside potential in the share.
LÄS MER
